Gyre Therapeutics今日宣布，中国国家药品监督管理局（NMPA）已正式授予其核心药物海酮内酯（研发代号F351）的新药上市申请（NDA）优先审评资格。该药物拟用于治疗慢性乙型肝炎（CHB）引发的肝纤维化。
此次优先审评资格的获得，意味着该药物的审评流程有望大幅提速，为亟需创新疗法的肝纤维化患者带来了新的希望。肝纤维化是慢性肝病进展为肝硬化和肝癌的关键环节，目前临床治疗选择有限。
Gyre Therapeutics今日宣布，中国国家药品监督管理局（NMPA）已正式授予其核心药物海酮内酯（研发代号F351）的新药上市申请（NDA）优先审评资格。该药物拟用于治疗慢性乙型肝炎（CHB）引发的肝纤维化。
此次优先审评资格的获得，意味着该药物的审评流程有望大幅提速，为亟需创新疗法的肝纤维化患者带来了新的希望。肝纤维化是慢性肝病进展为肝硬化和肝癌的关键环节，目前临床治疗选择有限。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.